About 20% of patients with ischaemic stroke have a preceding transient ischaemic attack, which is clinically defined as focal neurological symptoms of ischaemic origin resolving spontaneously. Failure to diagnose transient ischaemic attack is a wasted opportunity to prevent recurrent disabling stroke. Unfortunately, diagnosis can be difficult, due to numerous mimics, and to the absence of a specific test. New diagnostic tools are thus needed, in particular for radiologically silent cases, which correspond to the recommended tissue-based definition of transient ischaemic attack. As endothelial activation is a hallmark of cerebrovascular events, we postulated that this may also be true for transient ischaemic attack, and that it would be clinically relevant to develop non-invasive in vivo imaging to detect this endothelial activation. Using transcriptional and immunohistological analyses for adhesion molecules in a mouse model, we identified brain endothelial P-selectin as a potential biomarker for transient ischaemic attack. We thus developed ultra-sensitive molecular magnetic resonance imaging using antibody-based microparticles of iron oxide targeting P-selectin. This highly sensitive imaging strategy unmasked activated endothelial cells after experimental transient ischaemic attack and allowed discriminating transient ischaemic attack from epilepsy and migraine, two important transient ischaemic attack mimics. We provide preclinical evidence that combining conventional magnetic resonance imaging with molecular magnetic resonance imaging targeting P-selectin might aid in the diagnosis of transient ischaemic attack.
Introduction
Worldwide, stroke is the second cause of death and a leading cause of disability. As the population ages, stroke is predicted to cause 8 million deaths in 2030 (Strong et al., 2007) . Despite advances in the acute treatment of stroke, prevention remains the most effective way to reduce this burden.
About 20% of patients with ischaemic stroke have a preceding transient ischaemic attack (TIA) . Large cohort studies have demonstrated that TIA confers substantial short-and long-term risks of stroke, vascular events, myocardial infarction, cognitive impairment, and even death (Touzé et al., 2005; Giles and Rothwell, 2007; Sivakumar et al., 2014) . Thus, TIA is a 'warning' event that provides an opportunity for prevention, and new guidelines highlight the need for urgent assessment of those patients.
TIA was originally defined as a sudden onset of a neurologic dysfunction lasting less than 24 h, presumably resulting from focal cerebral ischaemia. Recent guidelines proposed a tissue-based definition, in which TIA is a transient episode of neurological dysfunction caused by focal ischaemia, without acute infarction (Easton et al., 2009) . These radiologically silent TIAs account for 20-50% of all time-defined TIAs. In practice, diagnosis of TIA remains challenging, and many differential diagnoses exist (TIA mimics, like migraines, seizures, or syncopes; Nadarajan et al., 2014) . Despite intensive efforts, the search for diagnostic biomarkers of ischaemic stroke has to date failed. This challenge could prove even more difficult in a less severe context like TIA. Experimental models might therefore prove helpful to identify TIA-specific signatures (such as biological markers).
Molecular imaging is an emerging field in the clinical practice, with encouraging developments for in vivo imaging of inflammation. We recently developed a new formulation of microsized particles of iron oxide (MPIO) targeted against VCAM1 to achieve ultra-sensitive molecular imaging of cerebrovascular inflammation in CNS disorders. This molecular MRI method reached unprecedented sensitivity and specificity to reveal endothelial cell activation in the brain with the possibility to reveal discrete and early stages of endothelium dysfunction (Montagne et al., 2012; Gauberti et al., 2013) . Molecular imaging of cerebrovascular inflammation thus appears as an interesting target for TIA, as endothelial dysfunction is at the origin of this pathology.
Our first goal was thus to optimize and characterize a preclinical mouse model of TIA, with laser Doppler-controlled ischaemia induced by middle cerebral artery occlusion, neurological activity recorded via somatosensory evoked potentials (SEPs), and potential brain lesions investigated by MRI. We thus determined the threshold of duration of occlusion not leading to MRI-evidenced brain lesion, and used it as a TIA model. Our second goal was to identify by polymerase chain reaction (PCR) and immunohistochemistry potential cerebrovascular inflammatory markers of TIA. Our final goal was to develop an MRI-based strategy selective for TIA, relying on the use of targeted MPIOs. Overall, we found that P-selectin targeted molecular MRI is suitable to non-invasively unmask the discrete endothelial responses to TIA.
Materials and methods

Animals
Experiments were performed on male Swiss mice ($37 g; CURB), in accordance with French laws (act no. 87-848; Ministère de l'Agriculture et de la Forêt) and European Communities Council Directives of November 24, 1986 (86/ 609/EEC) guidelines, and were approved by the local ethical committee (CENOMEXA). None of the experimental procedures induced mortality. Experiments were performed following the ARRIVE guidelines (www.nc3rs.org.uk), including randomization and blind analyses. For surgeries, mice were anaesthetized with isoflurane 5% and maintained under anaesthesia with 2% isoflurane in a 70%/30% gas mixture (N 2 O/O 2 ). The rectal temperature was maintained at 37 AE 0.5 C throughout using a feedback-regulated heating system.
Surgical procedure for transient ischaemic attack/ischaemic stroke and monitoring
We modified former models of selective neuronal necrosis or ischaemic stroke (Orset et al., 2007; Arsava et al., 2009; Morancho et al., 2012) . The bifurcation of distal middle cerebral artery (MCA) was exposed after a small craniotomy, preserving the dura. A blunted haematology micropipette (Hoecht; tip diameter: 250 mm) was applied with an angular approach (30 ) via a micromanipulator to induce MCA occlusion (MCAO) of selected durations (Fig. 1A) . Regional cerebral blood velocity was measured by laser Doppler flowmetry (Oxford Optronix). Sham surgery was performed by the same approach without compression. Permanent MCAO was performed by electrocoagulation. Analyses of brain lesion volumes (Fig. 1D ) led us to select 15 min MCAO as the optimum compression time to reproduce TIA, as it strictly complies with our criterion of a systematic and total absence of lesion on conventional MRI.
MRI of brain lesions
Imaging was carried out on a Pharmascan 7 T/12 cm system using surface coils (Bruker; Gauberti et al., 2013) . T 2 -weighted images to visualize infarction were acquired using MSME sequences (multi-spin multi-echo): echo time/repetition time: 51 ms/2500 ms with a 70 mm Â 70 mm Â 500 mm spatial resolution. Vascular permeability was assessed on 2D-TOF (time-of-flight) angiograms (echo time/repetition time: 12 ms/ 7 ms) and haemorrhage on T 2 * imaging (echo time/repetition time: 7.7 ms/500 ms) was performed. Lesion size was measured 24 h post-surgery on T 2 -weighted images using ImageJ (v1.45 r, NIH). In a longitudinal study, diffusion-weighted images (DWI) were acquired using a standard spin echo imaging modified with a Stejskal-Tanner gradient scheme. Parameters were: echo time/repetition time 2500 ms/29 ms, matrix size of 192 Â 192 giving an in plane resolution of 100 Â 78 mm, slice thickness of 0.75 mm, one direction diffusion gradient (in the frequency encoding direction) with a bfactor of 1000 s/mm 2 and one averaging.
Somatosensory evoked potentials
SEPs were recorded in anaesthetized TIA mice using a dedicated Keypoint system (Alpine biomed). The skin was retracted and a gold-plated ball electrode (Grass technologies) was placed over the right sensory cortex, 2 mm behind the bregma and 2 mm lateral to midline (Troncoso et al., 2000) . Subdermal needle electrodes were placed on the nose and on the back for reference and ground, respectively. Isoflurane was then reduced and N 2 O was replaced with medical air while checking the loss of withdrawal reflex. The SEP recording was then started and the left forepaw was stimulated using ring electrodes (intensity: 2 mA; duration: 0.2 ms; frequency: 2.7 Hz; sweep: 20). MCAO was started when stable cortical responses were obtained. SEPs were recorded every minute until total recovery of cortical responses. For analyses, we considered the first positive and negative (P1 and N1) waves.
Quantitative real-time polymerase chain reaction for vascular adhesion molecules
Reverse transcription and quantitative PCR were performed as previously described (Montagne et al., 2012) . Forward (F) and reverse (R) primers were: Vcam1 (F) gaacccaaacagaggcagag, (R) tgagcaggtcaggttcacag; P-selectin (Selp) (F) ggcaagtggaatgataacc, (R) ccatagaagcctgggtagca; Gapdh (F) tgcgacttcaacagcaactc, (R) atgtaggccatgaggtccac. Results were computed as follows: relative mRNA expression = E À(Ct of gene of interest) / E À (Ct of GAPDH) , where Ct is the threshold cycle value and E is efficiency.
Immunohistochemistry for vascular adhesion molecules
Brain sections were processed for immunohistochemistry as described previously (Gauberti et al., 2013) . Primary antibodies were goat anti-P-selectin (1:1000; AF737, R&D Systems), rat monoclonal anti-VCAM-1 [1:1000; A(429) from BD Bioscience] or rabbit anti-von Willebrand factor (VWF) (1:800; Dako). Primary antibodies were revealed using Fab'2 fragments of donkey anti-rat, goat, rabbit or mouse IgG linked to fluorescein isothiocyanate (FITC), tetramethylrhodamine (TRITC) or DyLight Õ 629 (1:600, Jackson ImmunoResearch). The number of VWF-, P-selectin-and VCAM1-positive vessels was quantified in the cortex on 12 consecutive sections (covering the area of the occlusion site, between bregma 1.18 and À0.7 mm). The specificity of immunostainings was checked by showing the absence of staining when primary antibodies were omitted or by performing immunostainings with a rat anti-mouse IgG monoclonal antibody (1:1000, Jackson ImmunoResearch) revealed with a FITC-coupled donkey anti-rat antibody (1:600, Jackson ImmunoResearch) ( Supplementary Fig. 1 ).
ELISA for soluble P-selectin
Sham, TIA or ischaemic stroke mice were blood sampled after 24 h [blood collected on buffered sodium citrate (0.129 mol/l, pH = 5.2) and centrifuged at 1500g for 15 min and at 12 000g for 2 min to collect platelet free plasmas]. Murine soluble Pselectin levels were quantified using the soluble P-selectin/ CD62P Quantikine Õ ELISA kit (R&D Systems).
Targeting-moiety conjugation to MPIOs and molecular imaging
MPIOs (diameter 1.08 mm) with p-toluenesulphonyl reactive surface groups (Invitrogen) were used for peptide conjugation (Montagne et al., 2012) . Purified polyclonal goat anti-mouse antibodies for P-selectin (R&D Systems, clone AF737), purified monoclonal rat anti-mouse antibodies for P-selectin (BD Biosciences, clone RB 40.34), purified monoclonal rat antimouse antibodies for VCAM1 (BD Biosciences, clone MVCAM A429) or control rat IgG (Jackson ImmunoResearch) were covalently conjugated to MPIOs in borate buffer with ammonium sulphate (pH 9.5), by incubation at 37 C for 48 h. Forty micrograms of targeting molecule (i.e. of each antibody) were used for the coating of 1 mg of reactive MPIOs. MPIOs were then washed in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) at 4 C and incubated for 24 h at room temperature, to block the remaining active groups. MPIOs were rinsed in PBS (0.1% BSA) and stored at 4 C. For contrast-enhanced MRI, a caudal catheter was placed and mice received intravenous injection of 2.0 mg Fe/kg of conjugated MPIOs (200 ml). Imaging was begun immediately after and lasted 20 min after particle administration. 3D T 2 *-weighted gradient echo imaging with flow compensation (spatial resolution of 70 mm Â 70 mm Â 70 mm interpolated to an isotropic resolution of 70 mm) with echo time/repetition time: 13.2 ms/200 ms and a flip angle of 21 was performed to visualize MPIOs (acquisition time: 20 min). All T 2 *-weighted images presented are minimum intensity projections of five consecutive slices (yielding a z-resolution of 350 mm). Signal voids quantification on 3D T 2 *-weighted images using automatic triangle threshold in ImageJ software (v1.45 r) (Gauberti et al., 2013) . Results are presented as volume of MPIOs-induced signal void divided by the volume of the structure of interest (in per cent).
The quality of conjugated MPIOs was systematically checked in a naïve mouse, by stereotaxic injection of lipopolysaccharide (1 mg in 1ml) in the striatum (0.5 mm anterior, 2.0 mm lateral, À3 mm ventral to the bregma).
Transient ischaemic attack mimics
Epileptic seizures were induced in awake mice by intraperitoneal injection of kainate (Tocris; 30 mg/kg in saline, 300 ml injected; Mulle et al., 1998) . recorded with a mean latency measured before occlusion of 11.2 AE 0.7 ms and 17.6 AE 2.0 ms, respectively, and a mean peak-to-peak amplitude of 77.2 AE 55.3 mV. The figure shows a horizontally stacked representative co-monitoring of regional cerebral blood velocity (continuous) and SEPs (every minute) for one representative mouse subjected to MCAO for 15 min. On the first curve, the P1 and N1 waves are highlighted. On this animal, P1 wave disappears 6 min after initiating MCAO and reappears (asterisk) 1 min after the end of occlusion, first inconstantly and then definitively 5 min after. The mean delays of disappearance and reappearance of SEPs relative to MCAO and MCA de-occlusion, respectively are reported on the top (mean AE SEM; n = 6).
Migraine was induced in awake mice, by the intraperitoneal injection of nitroglycerin at 10 mg/kg (VWR; in saline, 200 ml injected; Pradhan et al., 2014) . Nitroglycerin triggers migraine in humans, and induces migraine-like attacks in rodents, with hyperalgesia and conditioned place aversion (Pradhan et al., 2014) .
Molecular MRI was performed 24 h after inducing TIA mimics.
Statistics
Apart from ELISA studies, for which box-and-whisker plots are shown, data are presented as mean AE SEM and statistical analyses were performed with the Mann-Whitney's U-test, using the Statview software. For ELISA, comparisons between groups were done using ANOVA procedures in SAS 9.3.
Results
Vascular adhesion molecules as putative biomarkers of transient ischaemic attack
We first optimized previous approaches to have a mouse model corresponding to the tissue-based definition of TIA (Fig. 1A) . Doppler recordings (Fig. 1B and Supplementary  Fig. 2) show that, regardless of the duration of compression, MCAO reproducibly induced a robust decrease in regional cerebral blood velocity of $75%. MCAO lasting longer than 15 min were associated with brain infarctions within 24 h, which volumes increased with the duration of MCAO (Fig. 1C, D and Supplementary Fig. 3A) . Interestingly, for compressions lasting up to 15 min, no significant infarction was observed at the macro and microscopic levels, even after 3 months ( Supplementary Fig. 3B and C). Yet, MCAO of 15 min of compression were sufficient to induce transient neurological deficits. Indeed, when looking at SEPs, the P1/N1 cortical complex had systematically disappeared 5.8 AE 4.9 min after initiation of MCAO. The functional dysfunction was transient, as the P1/N1 cortical complex reappeared in 7.3 AE 5.2 min after the release of the artery (Fig. 1E) .
Based on these results, we considered that the model with MCAO for 15 min was a relevant model for the tissuebased definition of TIA: a vascular event with transient neurological disturbance, and no brain infarction on MRI.
Signs of inflammatory responses of the endothelium were then sought by RT-PCR for key cell adhesion molecules (VCAM1, ICAM1, E-selectin and P-selectin), 24 h after various durations of occlusion. Vcam1 transcription is activated in both cortices, for MCAO longer than 45 min only, with a 2-to 3.5-fold increase in the ipsilateral versus contralateral cortex ( Fig. 2A) . By contrast, the expression of Selp/P-selectin, Sele/E-selectin and Icam1 mRNA was activated in the ipsilateral cortex only, even for short MCAO, with differences between both cortices that could reach a factor 10 ( Fig. 2A and data not shown) . We then focused on VCAM1 and P-selectin. In immunohistological analyses, compared to control conditions, the proportion of VCAM1 and P-selectin-positive vessels in the MCA branch territory was increased after ischaemic stroke (13 and three times, respectively). Consistent with our mRNA study ( Fig.  2A) , while the expression of VCAM1 was unchanged following TIA, P-selectin levels were increased 3-fold versus controls ( Fig. 2B and C) . Neither VCAM1, nor P-selectin were detected in contralateral cortices ( Supplementary Fig.  4 ). However, increased levels of P-selectin in relation with cerebrovascular insult could not be detected using circulating soluble P-selectin as a surrogate marker. Indeed in mouse plasmas, soluble P-selectin levels measured by ELISA tended to increase with the severity of the insult, but this was not significant (Supplementary Fig. 5) . A small sample size study in the OXVASC population gave similar results (data not shown).
Combined T 2 -MRI with ultra-sensitive molecular MRI of P-selectin to positively diagnose transient ischaemic attack
We explored the possibility to directly detect brain P-selectin with targeted molecular imaging (Fig. 3A) . Using the approach we used for VCAM1 (Montagne et al., 2012; Gauberti et al., 2013) , we coupled MPIOs to a control immunoglobulin, or antibodies against P-selectin, AF737 and RB40.34. MPIOs were injected intravenously in mice 24 h after lipopolysaccharide injection in the striatum. In contrast to control IgG-coupled MPIOs, both P-selectin-targeted MPIOs induced ipsilateral hyposignals. The volume of signal void was 3-fold higher with AF737-MPIOs than with RB40.34-MPIOs ( Fig. 3B and C) . We thus selected AF737, and confirmed by in vivo optical imaging the interaction of AF737-MPIOs to the inflamed cerebrovasculature (Fig. 3D) . Like MPIOs-aVCAM1 (Montagne et al., 2012) , the detachment of MPIOs-aP-selectin from the vasculature was 70% after 2 h and was almost complete after 24 h ( Fig. 3E and F) .
Mice subjected to sham surgery, TIA or ischaemic stroke, were subjected (24 h after injury) to a control magnetic resonance angiography (MRA)/T 2 /T 2 * MRI and then injected with MPIOs-aP-selectin or MPIOs-aVCAM1 for molecular imaging. After ischaemic stroke, there were hyposignals in the MCA territory, with both MPIOsaVCAM1 (the ipsi-versus contralateral signal was doubled over sham mice) or MPIOs-aP-selectin (the ipsi-versus contralateral signal was 6.5-times higher than in sham mice) (Fig. 4A and B) . After TIA, there was no difference with MPIOs-aVCAM-1 compared to sham animals. By contrast, the ipsi/contralateral signal void with MPIOs-aPselectin was 6.5-times higher in TIA versus sham animals ( Fig. 4A and B) . Interestingly, signal voids were 1.5-fold higher 6 h after TIA than in sham mice, reflecting the initiation of cerebrovascular inflammation. Forty-eight hours after TIA, signal voids with MPIOs-aP-selectin were lower than at 24 h, but remained 2.5-fold higher than in sham mice (not significant, but indicative of a persistent inflammation; Supplementary Fig. 6 ).
Finally, MPIOs-aP-selectin and MPIOs-aVCAM1 were tested 24 h after inducing two frequent TIA mimics, i.e. migraine and epilepsy. In epilepsy, MPIOs-aP-selectin imaging was also identical to that in sham animals, while MPIOsaVCAM-1 signals were 15-times bigger in kainate-treated mice in the hippocampal area, as expected ( Fig. 5A and  B) . In migraine, MPIOs-aP-selectin imaging was unaltered, whereas MPIOs-aVCAM-1 signals were increased by 140%, as expected, in the area of the trigeminal nucleus caudalis, but also in the cerebellum (Fig. 5C and D) .
Together, these data show that molecular imaging for P-selectin in a context of transient neurological deficit without evidence of brain lesion by MRI could be used to diagnose TIA and discriminate it from migraine and epilepsy, two TIA mimics (Fig. 6 ).
Discussion
TIA patients are at risk of adverse events, especially stroke, and must thus be managed appropriately. Although the risk of early stroke might be stratified by clinical scale and/or imaging modalities (Giles et al., 2011) , the lack of an objective and selective strategy to diagnose TIA limits appropriate preventive therapies . In this study, we provided the proof-of-concept that molecular MRI of P-selectin could be used to positively diagnose TIA by disclosing endothelial activation. Here, we first implemented and optimized previous models to establish a preclinical mouse model of TIA complying with the tissue-based definition. This model combines the advantages of these previous models (Fieschi et al., 1975; Arsava et al., 2009; Pedrono et al., 2010; Morancho et al., 2012; Ejaz et al., 2015) : it is relatively non-invasive, robust, reproducible, easy to control, and preserves the dura. The main achievement with this model is the supply of an MRI-based objective evidence of TIA.
Considering clinical observations reporting an activation of the peripheral immune system (Jickling et al., 2012) , we speculated that TIA could also initiate a cerebrovascular inflammatory response. Like previous studies, we found upregulated cortical levels of adhesion molecules after ischaemic stroke (Wang and Feuerstein, 1995; Berti et al., 2002) . After TIA, while VCAM1 was unaffected, P-selectin (and to a lesser extent ICAM1 and E-selectin) was upregulated. Transmigration of inflammatory cells is normally initiated by tethering/rolling and then firm adhesion along the endothelium, two processes involving P-selectin and VCAM1, respectively. In our TIA model, only P-selectin is detectable at the endothelial surface, while both P-selectin and VCAM1 are present in the stroke model. The underlying mechanism for this differential expression remains unestablished, but most likely results from the milder severity of the insult after a TIA (Lee et al., 2004) , not leading to the actual adhesion/diapedesis of inflammatory cells. Alternatively, it could reflect the activation of distinct pathways of inflammatory transmigration ultimately leading to the recruitment of distinct immune cell subsets (Battistini et al., 2003) .
As soluble P-selectin levels could not be used as a surrogate marker of cerebrovascular P-selectin, we chose an alternative in vivo detection strategy, i.e. molecular imaging of P-selectin. Imaging approaches to visualize brainimmune interactions are very attractive, in particular molecular MRI, which combines high spatial and temporal resolutions, as well as fast acquisition time Gauberti et al., 2014) . In the past, others have used MRI, PET or multispectral optoacoustic tomography, and targeted P-selectin by using labelled ligands (e.g. 68 Ga-Fucoidan) or by coupling contrast agents to ligands (e.g. fucoidan, antibodies, sialyl Lewis X ) (Jin et al., 2009; McAteer et al., 2012; Beziere et al., 2014; Farr et al., 2014; Li et al., 2014) . In a stroke/neuroinflammation context, Pselectin has been targeted in molecular MRI studies, with disappointing results: P-selectin targeted USPIOs (ultrasmall particles of iron oxide) had a limited sensitivity and specificity in a mouse ischaemic stroke model (Jin et al., 2009 ) and a dual antibody-conjugated MPIOs, targeting both VCAM1 and P-selectin, did not show better images over single VCAM1 antibody-conjugated MPIOs in a model of acute inflammation in mice . More recently, sialyl Lewis X -conjugated silica iron nanoparticles have been tested in a rodent stroke model. However, the contrast agent was not specific for P-selectin and did not give better results than control particles. Moreover, signals were reported equally increased throughout the brain (Farr et al., 2014) .
MPIOs offer important advantages for endothelial-targeted imaging Gauberti et al., 2014) . First, their micrometre size range allows endovascular specificity, since MPIOs are not taken-up by endothelial cells and do not passively diffuse in the brain parenchyma even with blood-brain barrier breakdown. Second, MPIOs have a very short blood half-life of 50-100 s (Ye et al., 2008; Yang et al., 2010) , allowing imaging only MPIO binding to antigen immediately after injection. Third, MPIOs convey a large payload of iron oxide (usually 0.1-1.6 pg/particle), resulting in strong hypointense contrast effects that may extend up to 50 times the physical diameter of the particle. This phenomenon, known as the 'blooming effect', provides high sensitivity in vivo MRI detection, using only a small number of MPIO particles (Heyn et al., 2006; Shapiro et al., 2006) .
Here, we took advantage of our recent improvements of MPIOs-aVCAM1-based imaging (Montagne et al., 2012; Gauberti et al., 2013) to develop high quality MPIOs-aPselectin. In our mouse model, we demonstrated that MPIOs-aP-selectin can be used for a positive and selective MRI-based diagnosis of TIA (even in radiologically silent cases) and that this modality combined with T 2 MRI can experimentally discriminate TIA from at least two major TIA mimics, migraine and epilepsy. The superposition between molecular MRI study and patterns of staining in immunohistological analyses of perfused brains support our hypothesis that molecular imaging signals reflect specific endothelial P-selectin (translocated from Weibel-Palade bodies to the surface upon activation, and refueled by neosynthesis), even if we cannot exclude that, part of the signals could arise from adherent platelets. Noteworthy, unmasking an endothelial response after a very mild injury (15 min occlusion) demonstrates the sensitivity of our MRI-based approach.
Another interesting point is that positive signals with MPIOs-aP-selectin were evident on a relatively opened time-window (up to 48 h after TIA in our model). This observation first suggests that despite no evidence of macroscopic damage, TIA actually induces tissue sequelae, consistent with previous post-mortem histological findings (Ejaz et al., 2015 (Ejaz et al., , 2016 , but that our MRI modality noninvasively unmasks. Second, in the clinical setting, this time window gives a reasonable opportunity to process imaging, and to identify patients eligible for prevention.
Three characteristics of targeted MPIOs may limit their transfer for human applications (McAteer et al., 2010; Gauberti et al., 2014) . First, due to their polyurethane coat, current MPIOs are non-biodegradable and may therefore accumulate in tissues, even for long periods (McAteer et al., 2010; Roose et al., 2014) . However, development of new biodegradable coats is already ongoing (McAteer et al., 2010; Gauberti et al., 2014 ) and has even been tested in humans with new USPIOs like ferumoxytol (McBride et al., 2015) . Second, though iron toxicity could be questioned, the dose we used is in the range of that administered to humans for USPIO-based MRI of tumours, abdominal aortic aneurysms or ischaemic stroke (Saleh et al., 2004; Will et al., 2006; McBride et al., 2015) . No adverse effects had been reported in these studies. Third, the antibody carried by the MPIO might have a potential immunogenicity, but again, competitive ongoing strategies to increase the tolerance to therapeutic or diagnostic antibodies (single chain or humanized antibodies, nanobodies) should overcome this limit. Thus, targeted molecular MRI really has a good chance of becoming a reference technic in the clinical setting.
Until now, finding a biomarker for TIA has remained challenging, not necessarily regarding the identification of a target, but rather, due to a limited sensitivity of techniques. Here, we propose that molecular MRI targeting P-selectin could increase the reliability of TIA diagnosis especially for patients with silent conventional MRI. Interestingly, this strategy not only provides sensitive and specific radiological evidence but also supports clinical conclusions, if reported neurological symptoms are consistent with the topography of the vascular territory with MPIOs signals. In conclusion, the proof-of-concept discovered in our preclinical models encourages future studies to investigate the specificity, sensitivity and feasibility of molecular MRI targeting P-selectin for the diagnosis of TIA.
